LAVAL, QC, Aug. 2, 2016 /CNW Telbec/ - ProMetic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it will report its financial
results for the second quarter ended June 30, 2016 on Thursday August 11,
2016 after market close.
ProMetic will host a conference call at 11:00am (ET) on Friday August 12,
2016. The telephone numbers to access the conference call are 647-427-7450 and 1-888-231-8191. A live audio webcast of the
conference call will be available via: http://event.on24.com/r.htm?e=1233243&s=1&k=9FECEF76FF5F22B76FB13ABE2DCF57E1.
An audio replay of the call will be available as of Friday August 12, 2016, at 2:00pm (ET). The numbers to access the audio replay are (416) 849-0833 and 1 (855) 859-2056 using the
following password: 56333260.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity
technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to
develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic
products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation
as well as certain nephropathies. A number of both the plasma-derived and small molecule products are under development for orphan
drug indications. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the
U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that
involve risks and uncertainties. These statements are "forward -looking" because they are based on our current expectations about
the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions
turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture,
and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ
from our current expectations in ProMetic's Annual Information Form for the year ended December 31,
2015, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that
any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new
information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws
and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
